Core B: Clinical Core

核心 B：临床核心

• 批准号: 9761403
• 负责人: Jesse Benjamin Mez
• 金额: $ 69.91万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-15 至 2021-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9761403
• 关键词: African American; Agreement; Alzheimer' s Disease; Area; Autopsy; Biological Markers; Blood; Blood Vessels; Boston; Brain; Cells; Cessation of life; Clinical; Clinical Research; Clinical Trials; Cognitive; Communities; Consensus; Consent; DNA; Data; Data Coordinating Center; Data Set; Databases; Dementia; Development; Diagnosis; Diagnostic; Factor Analysis; Foundations; Funding; Genetic; Genetic Diseases; Genotype; Grant; Industry; International; Life; MRI Scans; Magnetic Resonance Imaging; Manufactured football; Methods; Neuropsychological Tests; Participant; Pathologic; Patient Recruitments; Pilot Projects; Prevention; Registries; Research; Research Personnel; Risk Factors; Sampling; Scanning; Source; Specimen; Time; United States National Institutes of Health; Universities; Work; aging brain; biomarker development; brain tissue; chronic traumatic encephalopathy; cognitive neuroscience; cohort; cooperative study; data management; data quality; data registry; data sharing; design; diagnosis quality; genomic biomarker; head impact; in vivo; mild cognitive impairment; multidisciplinary; neuroimaging; neuropathology; prognostic; programs; recruit; repository; research study; sample collection; statistics; symposium

The BU ADC Clinical Core (CC) conducts and enhances cutting-edge Alzheimer’s disease (AD) research. CC registry data and subject participation support local and national clinical research studies. We have successfully maintained approximately 20% African American representation in the registry. The CC obtains research-quality MRI scans on registry participants and CC investigators are actively engaged in, and make major contributions to national and international AD research endeavors, including genetics and genomics, biomarker development, cognitive and functional assessment, and cognitive neuroscience. CC investigators have also made significant contributions to the clinical description, diagnosis, and risk factor analysis of chronic traumatic encephalopathy (CTE). We have fully integrated the examination of CTE, with an emphasis on the comparison of CTE and AD, and have included a cohort of former National Football League (NFL) players in the CC registry. We also have integrated CC activities and methods with those of several funded studies of CTE affiliated with the CC. During the next funding cycle, the CC will have the following specific aims: Aim 1: To evaluate and longitudinally examine a registry of approximately 425 participants, comprised of: 50 cognitively normal controls without subjective cognitive complaints (SCC); 125 controls with SCC; 100 subjects with mild cognitive impairment; 75 subjects with mild-moderate AD dementia; and 75 former NFL players with extensive repetitive head impact exposure. Aim 2: To provide data and a source for well-characterized participants for local and national research studies on brain aging, AD spectrum, and CTE research. Research-quality diagnoses will be made on all participants through multidisciplinary diagnostic consensus conferences. High quality data will be collected and submitted to the National Alzheimer’s Coordinating Center (NACC) for data sharing with qualified investigators. The Registry was designed to meet the recruitment needs of the local and national AD research community. Aim 3: To obtain brain donation consents for a minimum of 75% of registry participants and to work with the Neuropathology Core (NPC) to successfully obtain brain tissue from a minimum of 90% of consented participants upon death. The CC and the NPC will examine clinicopathological agreements, with a special emphasis on the comparison of AD and CTE. Aim 4. To collect blood and CSF products from registry participants. The CC will work closely with the NPC to integrate the collection of specimens with the analysis, banking, and distribution of specimens. We will extract DNA and genotype APOE and provide samples to qualified AD and CTE researchers, the National Cell Repository for Alzheimer’s Disease and the Alzheimer’s Disease Genetics Consortium. Aim 5: To conduct research-quality MRI scans on a minimum of 85% of the registry to support AD- and CTE-related research. We will upload MRI data to NACC. The Neuroimaging section of the CC will conduct post-processing of scans and will make the data available to CC investigators and to others in the AD and CTE research communities.

北卡罗来纳大学ADC临床核心(CC)进行并加强了阿尔茨海默病(AD)的尖端研究。 CC登记数据和受试者参与为地方和国家临床研究提供支持。我们有 在登记册上成功地保持了大约20%的非洲裔美国人的代表性。消委会获得 对登记参与者和CC调查人员积极参与的研究质量MRI扫描，并做出 对国内和国际AD研究工作的重大贡献，包括遗传学和基因组学， 生物标记物开发、认知和功能评估以及认知神经科学。CC调查员 在慢性阻塞性肺疾病的临床描述、诊断和危险因素分析方面也做出了重大贡献 创伤性脑病。我们已经全面整合了对CTE的审查，重点是 CTE和AD的比较，并包括了一批前国家橄榄球联盟(NFL)球员 CC注册表。我们还将CC活动和方法与CTE的几项资助研究的活动和方法相结合 隶属于CC。在下一个供资周期，协调委员会将有以下具体目标： 目标1：评估和纵向审查一份约有425名参与者的登记册，包括 研究对象：50名认知正常、无主观认知主诉(SCC)的对照组；125名有SCC的对照组；100名 轻度认知障碍的受试者；75名轻中度AD痴呆症的受试者；以及75名前NFL球员 有大量重复性头部撞击暴露。目标2：提供数据和来源 参与当地和国家关于脑老化、AD谱和CTE研究的研究。 将通过多学科诊断共识对所有参与者进行研究质量诊断 会议。将收集高质量的数据并提交给国家阿尔茨海默氏症协调中心 (NACC)与合格调查人员共享数据。书记官处是为满足征聘需要而设计的 地方和国家AD研究社区的成员。目标3：以最低成本获得脑部捐献同意 并与神经病理学核心(NPC)合作，成功地获得 至少90%的参与者同意死亡时的脑组织。消委会和全国人大将 检查临床病理结果，特别强调AD和CTE的比较。目标4.目标 收集登记参与者的血液和脑脊液产品。消委会将与全国人大密切合作，将 标本收集与标本的分析、储存和分配。我们将提取DNA并 并向合格的AD和CTE研究人员提供样本，国家细胞库 阿尔茨海默病和阿尔茨海默病遗传学联合会。目标5：开展高质量的研究 MRI扫描注册表中至少85%的区域，以支持AD和CTE相关研究。我们将上传 核磁共振数据传给NACC。CC的神经成像科将对扫描进行后处理，并将 CC调查人员以及AD和CTE研究社区中的其他人可以获得的数据。